Angiogeneseinhibitoren zur Behandlung Angiodysplasie-assoziierter gastrointestinaler Blutungen

Schlüsselwörter

Angiodysplastie - Morbus Osler - Angiogenese - Gastrointestinale Blutungen - Thalidomid

Keywords

Angiodysplasias - Osler’s disease - Angiogenesis - gastrointestinal bleeding - thalidomide

Literatur

• 1 Amato de R J, Loughnan M S, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis.  Proc Natl Acad Sci USA. 1994;  91 4082-4085
• 2 Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn’s disease.  Gut. 2002;  50 196-200
• 3 Bauditz J, Schachschal G, Wedel S, Lochs H. Thalidomide for treatment of severe intestinal bleeding.  Gut. 2004;  53 609-613
• 4 Bauditz J, Lochs H, Voderholzer W. Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide.  Endoscopy. 2006;  38 1036-1039
• 5 Cirulli A, Liso A, D’Ovidio F. et al . Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia.  Acta Haematol. 2003;  110 29-32
• 6 Junquera F, Feu F, Papo M. et al . A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia.  Gastroenterology. 2001;  121 1073-1079
• 7 Junquera F, Saperas E, de Torres I, Vidal M T, Malagelada J R. Increased expression of angiogenic factors in human colonic angiodysplasia.  Am J Gastroenterol. 1999;  94 1070-1076
• 8 Kabbinavar F, Hurwitz H I, Fehrenbacher L. et al . Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.  J Clin Oncol. 2003;  21 60-65
• 9 Kurstin R. Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease.  Oncology. 2002;  16 21-24
• 10 Madhusudan S, Deplanque G, Braybrooke J P. et al . Antiangiogenic therapy for von Hippel-Lindau disease.  JAMA. 2004;  291 943-944
• 11 Nardone G, Rocco A, Balzano T, Budillon G. The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract.  Aliment Pharmacol Ther. 1999;  13 1429-1436
• 12 Perez-Encinas M, Rabunal Martinez M J, Bello Lopez J L. Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia?.  Haematologica. 2002;  87 34-35
• 13 Scaglione G, Pietrini L, Russo F. et al . Long-acting octreotide as rescue therapy in chronic bleeding from gastrointestinal angiodysplasia.  Aliment Pharmacol Ther. 2007;  26 935-942
• 14 Shurafa M, Kamboj G. Thalidomide for the treatment of bleeding angiodysplasias.  Am J Gastroenterol. 2003;  98 221-222
• 15 van Heeckeren W J, Sanborn S L, Narayan A. et al . Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.  Curr Opin Hematol. 2007;  14 468-480
• 16 Vase P. Estrogen treatment of hereditary hemorrhagic telangiectasia. A double-blind controlled clinical trial.  Acta Med Scand. 1981;  209 393-396